Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification

Breast Cancer Research and Treatment

Volumn 151, Issue 2, 2015, Pages 325-333

  Aleskandarany, Mohammed A ^a,b   Soria, D ^c   Green, A R ^a   Nolan, C ^a   Diez Rodriguez, Maria ^a   Ellis, I O ^a   Rakha, E A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b MENOUFIA UNIVERSITY   (Egypt)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Breast cancer; Immunohistochemistry; Metastasis; Risk stratification algorithm

Indexed keywords

TUMOR MARKER;

ALGORITHM; BREAST NEOPLASMS; CANCER STAGING; DECISION TREE; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ALGORITHMS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DECISION TREES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS;

EID: 84937759990     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3406-3     Document Type: Article

References (33)

1. Rabbani F, Koppie TM, Charytonowicz E, Drobnjak M, Bochner BH, Cordon-Cardo C (2007) Prognostic significance of p27(Kip1) expression in bladder cancer. BJU Int 100(2):259–263
2. Nguyen DX, Massague J (2007) Genetic determinants of cancer metastasis. Nat Rev Genet 8(5):341–352
3. Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456
4. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). Nat Clin Pract Oncol 2(8):416–422
5. Cruz JA, Wishart DS (2007) Applications of machine learning in cancer prediction and prognosis. Cancer Inform 11(2):55–77
6. Kotsiantis SB (2007) Supervised machine learning: a review of classification techniques. Informatica 31:249–268
7. Salzberg S (1994) C4.5: programs for machine learning by J. Ross Quinlan. Morgan Kaufmann Publishers Inc, 1993. Mach Learn 16(3):235–240
8. Quinlan JR (1993) C4.5: programs for machine learning. Morgan Kaufmann Publishers, Inc., Los Altos
9. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer (Journal International du Cancer) 116(3):340–350
10. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet J-S, Akslen LA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302–2310
11. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO (2004) Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91(8):1532–1542
12. Albasri A, Seth R, Jackson D, Benhasouna A, Crook S, Nateri AS, Chapman R, Ilyas M (2009) C-terminal Tensin-like (CTEN) is an oncogene which alters cell motility possibly through repression of E-cadherin in colorectal cancer. J Pathol 218(1):57–65
13. Ling LJ, Wang S, Liu XA, Shen EC, Ding Q, Lu C, Xu J, Cao QH, Zhu HQ, Wang F (2008) A novel mouse model of human breast cancer stem-like cells with high CD44 + CD24-/lower phenotype metastasis to human bone. Chin Med J (Engl) 121(20):1980–1986
14. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JFR, Aparicio S, Ellis IO, Brenton JD et al (2006) A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26(10):1507–1516
15. Zhang H, Rakha EA, Ball GR, Spiteri I, Aleskandarany M, Paish EC, Powe DG, Macmillan RD, Caldas C, Ellis IO et al (2010) The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat 121(1):41–51
16. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD et al (2007) A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26(10):1507–1516
17. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR (2011) MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat 127(3):591–599
18. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr (1985) Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109(8):716–721
19. Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, Lee AH (2009) The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 45(10):1780–1787
20. Altman DG, Bland JM (1994) Statistics Notes: diagnostic tests 2: predictive values. BMJ 309(6947):102
21. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65
22. Liu Y, Kulesz-Martin MF (2006) Sliding into home: facilitated p53 search for targets by the basic DNA binding domain. Cell Death Differ 13(6):881–884
23. Goodsell DS (2002) The molecular perspective: Bcl-2 and apoptosis. Oncologist 7(3):259–260
24. Rakha EA, Putti TC, El-Rehim DMA, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4):495–506
25. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376
26. Aleskandarany MA, Negm OH, Green AR, Ahmed MA, Nolan CC, Tighe PJ, Ellis IO, Rakha EA (2014) Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Res Treat 145(2):339–348
27. Aleskandarany MA, Rakha EA, Ahmed MA, Powe DG, Paish EC, Macmillan RD, Ellis IO, Green AR (2010) PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 122(1):45–53
28. Zardavas D, Phillips WA, Loi S (2014) PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Res 16(1):201
29. Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1(2):149–153
30. Townson JL, Chambers AF (2006) Dormancy of solitary metastatic cells. Cell Cycle 5(16):1744–1750
31. Abdel-Fatah TM, Powe DG, Agboola J, Adamowicz-Brice M, Blamey RW, Lopez-Garcia MA, Green AR, Reis-Filho JS, Ellis IO (2010) The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 220(4):419–434
32. Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9(6):606–616
33. Callagy GM, Webber MJ, Pharoah PD, Caldas C (2008) Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 8:153